Poulaki V - Search Results

1

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP. Usui T, et al. Among authors: poulaki v. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74. doi: 10.1167/iovs.03-0106. Invest Ophthalmol Vis Sci. 2004. PMID: 14744874

2

The role of advanced glycation end products in retinal microvascular leukostasis.

Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP. Moore TC, et al. Among authors: poulaki v. Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4457-64. doi: 10.1167/iovs.02-1063. Invest Ophthalmol Vis Sci. 2003. PMID: 14507893

3

ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.

Kaochar S, Dong J, Torres M, Rajapakshe K, Nikolos F, Davis CM, Ehli EA, Coarfa C, Mitsiades N, Poulaki V. Kaochar S, et al. Among authors: poulaki v. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):132-143. doi: 10.1167/iovs.17-22454. Invest Ophthalmol Vis Sci. 2018. PMID: 29332125 Free PMC article.

4

Retinoblastoma: genetics and pathology.

Poulaki V, Mukai S. Poulaki V, et al. Int Ophthalmol Clin. 2009 Winter;49(1):155-64. doi: 10.1097/IIO.0b013e3181924bc2. Int Ophthalmol Clin. 2009. PMID: 19125074 Review. No abstract available.

5

The role of Fas and FasL as mediators of anticancer chemotherapy.

Poulaki V, Mitsiades CS, Mitsiades N. Poulaki V, et al. Drug Resist Updat. 2001 Aug;4(4):233-42. doi: 10.1054/drup.2001.0210. Drug Resist Updat. 2001. PMID: 11991678 Review.

6

Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.

Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Mitsiades N, et al. Among authors: poulaki v. Cancer Res. 2000 Aug 1;60(15):4122-9. Cancer Res. 2000. PMID: 10945619

7

The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.

Mitsiades CS, Poulaki V, Mitsiades N. Mitsiades CS, et al. Among authors: poulaki v. J Endocrinol. 2003 Aug;178(2):205-16. doi: 10.1677/joe.0.1780205. J Endocrinol. 2003. PMID: 12904168 Review.

8

Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.

Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Mitsiades N, et al. Among authors: poulaki v. Cancer Res. 2001 Mar 15;61(6):2704-12. Cancer Res. 2001. PMID: 11289151

9

Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.

Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC. Mitsiades N, et al. Among authors: poulaki v. Expert Opin Investig Drugs. 2001 Jun;10(6):1075-84. doi: 10.1517/13543784.10.6.1075. Expert Opin Investig Drugs. 2001. PMID: 11772236 Review.

10

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.

Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Mitsiades N, et al. Among authors: poulaki v. Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30. doi: 10.1517/13543784.10.8.1521. Expert Opin Investig Drugs. 2001. PMID: 11772267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page